Get the Stockscreener App
0.30
1.54%
-0.0047
After Hours:
.31
0.01
+3.33%
Intensity Therapeutics Inc stock is traded at $0.30, with a volume of 6.66M.
It is down -1.54% in the last 24 hours and up +29.20% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.3047
Open:
$0.3047
24h Volume:
6.66M
Relative Volume:
1.43
Market Cap:
$14.72M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.2539
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
+4.86%
1M Performance:
+29.20%
6M Performance:
-84.13%
1Y Performance:
-91.07%
1-Day Range:
$0.273
$0.31
1-Week Range:
$0.2701
$0.3774
52-Week Range:
$0.1853
$3.5282
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.30 | 14.95M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Will Intensity Therapeutics Inc. benefit from macro trendsWeekly Profit Recap & High Win Rate Trade Tips - newser.com
How to integrate Intensity Therapeutics Inc. into portfolio analysis toolsJuly 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
Volatility clustering patterns for Intensity Therapeutics Inc.Market Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Has Intensity Therapeutics Inc. found a price floor2025 Support & Resistance & Momentum Based Trading Signals - newser.com
Intensity Therapeutics Inc. stock trendline breakdownJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Chart based analysis of Intensity Therapeutics Inc. trendsJuly 2025 Rallies & Technical Pattern Alert System - newser.com
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Can volume confirm reversal in Intensity Therapeutics Inc.Trade Performance Summary & Risk Controlled Swing Alerts - newser.com
Published on: 2025-10-10 05:08:00 - newser.com
Published on: 2025-10-09 05:57:28 - newser.com
Using flow based indicators on Intensity Therapeutics Inc.July 2025 EndofMonth & Long-Term Safe Investment Ideas - newser.com
Using Ichimoku Cloud for Intensity Therapeutics Inc. technicals2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
What analysts say about Accelerate Diagnostics Inc stockFibonacci Extensions & Fast Profit Stock Ideas - earlytimes.in
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction - The Globe and Mail
Is Intensity Therapeutics Inc. reversing from oversold territory2025 Momentum Check & High Accuracy Investment Signals - newser.com
Chart based exit strategy for Intensity Therapeutics Inc.Weekly Volume Report & High Conviction Buy Zone Picks - newser.com
Is Intensity Therapeutics Inc. stock a buy before product launchesJuly 2025 Chart Watch & Momentum Based Trading Ideas - newser.com
How to manage a losing position in Intensity Therapeutics Inc.2025 Winners & Losers & Fast Exit and Entry Strategy Plans - newser.com
Custom strategy builders for tracking Intensity Therapeutics Inc.2025 Market WrapUp & Long-Term Capital Growth Strategies - newser.com
Shaping the Future of Oncology: Breast Cancer Therapeutics Market Poised for Strong Growth in 2025 - PharmiWeb.com
Is Intensity Therapeutics Inc a good long term investmentMACD Trading Signals & Swing Trade Smarter With Data Insights - Early Times
Real time alert setup for Intensity Therapeutics Inc. performanceJuly 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Should you hold or exit Intensity Therapeutics Inc. nowDividend Hike & Proven Capital Preservation Tips - newser.com
Is it time to cut losses on SKINTrade Volume Summary & High Conviction Buy Zone Alerts - newser.com
Buyout Rumor: What are DHI Group Inc.’s technical support levelsPortfolio Value Summary & High Conviction Buy Zone Alerts - خودرو بانک
Chart overlay techniques for tracking Intensity Therapeutics Inc.Quarterly Portfolio Report & Long-Term Capital Growth Strategies - newser.com
Will breakout in Intensity Therapeutics Inc. lead to full recoveryRisk Management & Real-Time Chart Breakout Alerts - newser.com
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):